These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

316 related articles for article (PubMed ID: 15964291)

  • 21. A detailed analysis of menstrual blood loss in women using Norplant and Nestorone progestogen-only contraceptive implants or vaginal rings.
    Fraser IS; Weisberg E; Minehan E; Johansson ED
    Contraception; 2000 Apr; 61(4):241-51. PubMed ID: 10899479
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Ovarian function during use of Nestorone(R) subdermal implants.
    Brache V; Massai R; Mishell DR; Moo-Young AJ; Alvarez F; Salvatierra AM; Cochon L; Croxatto H; Robbins A; Faundes A
    Contraception; 2000 Mar; 61(3):199-204. PubMed ID: 10827334
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Impact of body mass index on suppression of follicular development and ovulation using a transdermal patch containing 0.55-mg ethinyl estradiol/2.1-mg gestodene: a multicenter, open-label, uncontrolled study over three treatment cycles.
    Westhoff CL; Reinecke I; Bangerter K; Merz M
    Contraception; 2014 Sep; 90(3):272-9. PubMed ID: 24969733
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ovarian function with the contraceptive vaginal ring or an oral contraceptive: a randomized study.
    Duijkers IJ; Klipping C; Verhoeven CH; Dieben TO
    Hum Reprod; 2004 Nov; 19(11):2668-73. PubMed ID: 15333593
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Ovarian activity, cycle behavior and tolerance of low dosage oral contraceptives: a comparative study].
    Rossmanith WG; Wirth U; Gasser S; Thun B; Steffens D
    Zentralbl Gynakol; 1997; 119(11):538-44. PubMed ID: 9480608
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Increased impact of a contraceptive vaginal ring with ethinyl estradiol and nestorone on C-reactive protein.
    Rad M; Burggraaf J; Sitruk-Ware RL; de Kam ML; Cohen AF; Kluft C
    Steroids; 2012 Nov; 77(13):1483-6. PubMed ID: 22982353
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Lower hormone dosage with improved cycle control.
    Vree M
    Eur J Contracept Reprod Health Care; 2002 Dec; 7 Suppl 2():25-30; discussion 37-9. PubMed ID: 12659399
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Vaginal ring contraception.
    Kerns J; Darney P
    Contraception; 2011 Feb; 83(2):107-15. PubMed ID: 21237335
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Follicular growth during contraceptive pill or vaginal ring treatment depends on the day of ovulation in the pretreatment cycle.
    Duijkers IJ; Verhoeven CH; Dieben TO; Klipping C
    Hum Reprod; 2004 Nov; 19(11):2674-9. PubMed ID: 15319379
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The use of serum segesterone acetate levels to assess adherence of trial participants with a contraceptive vaginal ring.
    Thompson RL; Hu J; Custodio P; Dart C; Jensen JT
    Contraception; 2022 Apr; 108():61-64. PubMed ID: 34971614
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Bleeding patterns of women using extended regimens of the contraceptive vaginal ring.
    Barreiros FA; Guazzelli CA; de Araújo FF; Barbosa R
    Contraception; 2007 Mar; 75(3):204-8. PubMed ID: 17303490
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The vaginal contraceptive pill.
    Coutinho E
    IPPF Med Bull; 1985 Feb; 19(1):2-3. PubMed ID: 12339969
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Vaginal contraception with steroids].
    Levrier M
    Contracept Fertil Sex (Paris); 1993 Nov; 21(11):837-8. PubMed ID: 12287400
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Vaginal rings for contraception: endocrine parameters.
    Olsson SE
    Adv Contracept Deliv Syst; 1992; 8(1-2):71-3. PubMed ID: 12285565
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phase II dose-finding study on ovulation inhibition and cycle control associated with the use of contraceptive vaginal rings containing 17β-estradiol and the progestagens etonogestrel or nomegestrol acetate compared to NuvaRing.
    Duijkers I; Klipping C; Heger-Mahn D; Fayad GN; Frenkl TL; Cruz SM; Korver T
    Eur J Contracept Reprod Health Care; 2018 Aug; 23(4):245-254. PubMed ID: 30203681
    [TBL] [Abstract][Full Text] [Related]  

  • 36. New delivery systems in contraception: vaginal rings.
    Johansson ED; Sitruk-Ware R
    Am J Obstet Gynecol; 2004 Apr; 190(4 Suppl):S54-9. PubMed ID: 15105799
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A randomized study of the effect of mifepristone alone or in conjunction with ethinyl estradiol on ovarian function in women using the etonogestrel-releasing subdermal implant, Implanon®.
    Weisberg E; Croxatto HB; Findlay JK; Burger HG; Fraser IS
    Contraception; 2011 Dec; 84(6):600-8. PubMed ID: 22078189
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pituitary and gonadal function during the use of progesterone- or progesterone-estradiol-releasing vaginal rings.
    Toivonen J
    Int J Fertil; 1980; 25(2):106-11. PubMed ID: 6117523
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A contraceptive vaginal ring releasing ethinyl estradiol and the progestin ST-1435: bleeding control, serum steroid concentrations, serum lipids and serum chemistry.
    Laurikka-Routti M; Haukkamaa M; Heikinheimo O
    Contraception; 1990 Jul; 42(1):111-20. PubMed ID: 2387151
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Individualization of low-dose oral contraceptives. Pharmacological principles and practical indications for oral contraceptives].
    Cianci A; De Leo V
    Minerva Ginecol; 2007 Aug; 59(4):415-25. PubMed ID: 17923832
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.